InsiderClue
Stocks · Health care · Pharmaceutical Preparations

OS Therapies Inc

OSTX Clue Score17
United States Fiscal year ends December CIK 0001795091
$1.62 +0.00% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.62 −20.59% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 1 Aug 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−4.3Net income−7.8EPS, diluted−1.46Fiscal year 2024Operating income−6.8Net income−8.9EPS, diluted−1.28Fiscal year 2025Operating income−28.7Net income−28.8EPS, diluted−0.98
FY2023FY2024FY2025
Operating income −4.3 −6.8 −28.7
Net income −7.8 −8.9 −28.8
Growth
EPS, diluted −1.46 −1.28 −0.98

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−3.0Fiscal year 2024Operating cash flow−7.3Fiscal year 2025Operating cash flow−14.2Capital expenditure−0.5Free cash flow−14.7
FY2023FY2024FY2025
Operating cash flow −3.0 −7.3 −14.2
Capital expenditure n/a n/a −0.5
Free cash flow n/a n/a −14.7
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash0.0Shareholders’ equity−24.0Fiscal year 2024Cash5.5Shareholders’ equity−3.3Fiscal year 2025Cash0.3Shareholders’ equity−6.1
FY2023FY2024FY2025
Cash 0.0 5.5 0.3
Shareholders’ equity −24.0 −3.3 −6.1

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
−976.3% −160.4% −420.4%
Balance and payout
3,109.2% 85.3% 173.5%